TCR-Therapy Pipeline

DelveInsight’s, “TCR Therapy- Pipeline Insight, 2025” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in TCR Therapy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

TCR Therapy: Understanding

TCR Therapy: Overview

The T-cell receptor (TCR) is a molecule found on the surface of T cells, or T lymphocytes, that is responsible for recognizing fragments of antigen as peptides bound to major histocompatibility complex (MHC) molecules. The binding between TCR and antigen peptides is of relatively low affinity and is degenerate, that is, many TCRs recognize the same antigen peptide and many antigen peptides are recognized by the same TCR.

The TCR is a disulfide-linked membrane-anchored heterodimeric protein normally consisting of the highly variable alpha (α) and beta (β) chains expressed as part of a complex with the invariant CD3 chain molecules. T cells expressing this receptor are referred to as α:β (or αβ) T cells, though a minority of T cells express an alternate receptor, formed by variable gamma (γ) and delta (δ) chains, referred as γδ T cells. Each chain is composed of two extracellular domains: Variable (V) region and a Constant (C) region, both of Immunoglobulin superfamily (IgSF) domain forming antiparallel β-sheets. The Constant region is proximal to the cell membrane, followed by a transmembrane region and a short cytoplasmic tail, while the Variable region binds to the peptide/MHC complex.

Successfully rearranged TCRs are expressed at the T cell surface and audition for selection on thymic self-pMHC ligands. The net result of thymic selection is that the post-selection repertoire is largely purged of most clonotypes. Typically, only one in a hundred thymocytes are thought to be granted access to the periphery. Assessing the relative distribution of TCR clonotypes has long been a challenge in the naive pool because of low precursor frequency. Nevertheless, identifying the factors that shape the composition of the naive repertoire is critical to understanding of protective T cell-mediated immunity because naive lymphocytes represent the precursor pool from which all immune responses arise.

Improving the function of TCR-engineered T cells is critical to overcome inhibitory factors within the tumor microenvironment and elicit tumor regression. Many efforts to enhance antigen reactivity and circumvent T cell tolerance have focused on increasing TCR signal strength and generating highly functional T cells. Immune checkpoint proteins, such as PD-1 and CTLA-4, can prevent the activation of T cells in immune system. A recent study demonstrating the benefits of this approach created CD8+ T cells expressing two additional receptors; a gp100 antigen-specific TCR and a melanoma-associated chondroitin sulfate proteoglycan specific CAR. These T cells using combined recognition pathways showed greater efficacy by by-passing the mechanisms by which tumor cells escape immune recognition. In conclusion, TCR-engineered T cells therapy, in combination with drugs targeting chemokines, cytokines, and immune checkpoint proteins, may obtain better clinical responses in future treatments.

"TCR Therapy- Pipeline Insight, 2025" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the TCR Therapy pipeline landscape is provided which includes the disease overview and TCR Therapy treatment guidelines. The assessment part of the report embraces, in depth TCR Therapy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, TCR Therapy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence TCR Therapy R&D. The therapies under development are focused on novel approaches to treat/improve TCR Therapy. 

TCR Therapy Emerging Drugs Chapters

This segment of the TCR Therapy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, II/III I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

TCR Therapy Emerging Drugs

• Brenetafusp: Immunocore 

IMC-F106C is an ImmTAC targeting PRAME for patients with HLA-A02, which is expressed in approximately 40% of Western populations (United States, Canada, EU). In order to expand the potential of TCR therapy targeting PRAME, the Company is developing IMC-T119C, a first-in-class ImmTAC product candidate targeting a PRAME peptide presented by HLA-A24. HLA-24 is an HLA-type that is estimated to be present in 60% of people in Japan and 15-20% in Western populations. Currently the drug is in Phase III stage of clinical trial evaluation for the treatment of patients with 1L advanced, cutaneous melanoma.

• Pemvidutide - Altimmune

Pemvidutide (proposed INN, formerly known as ALT-801) is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and NASH. Activation of the GLP-1 and glucagon receptors is believed to mimic the complementary effects of diet and exercise on weight loss, with GLP-1 suppressing appetite and glucagon increasing energy expenditure. By combining GLP-1 and glucagon activity in a single peptide, pemvidutide has the potential to achieve weight loss comparable to bariatric surgery. Pemvidutide also has been shown to increase the breakdown of fat and its mobilization within the liver, which may have beneficial effects on insulin resistance, a common problem in people with obesity. Pemvidutide incorporates the EuPortTM domain, a proprietary technology that increases its serum half-life for weekly dosing while slowing the entry of pemvidutide into the bloodstream, which may improve its tolerability. In a Phase I clinical study, pemvidutide demonstrated striking reductions in body weight, liver fat and serum lipids. Currently the drug is in Phase II stage of its development for the treatment of NASH.

• TSC 101: TScan Therapeutics 

TSC-101 is the first clinical cell therapy product targeting minor histocompatibility antigen HA-2 to treat leukemia and prevent relapse following hematopoietic cell transplantation. TSC-101 is an investigational T cell receptor-engineered T cell therapy (TCR-T) developed by TScan Therapeutics, targeting the minor histocompatibility antigen HA-2. It is designed to eliminate residual disease and prevent relapse in patients with hematologic malignancies, such as acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL), following allogeneic hematopoietic cell transplantation (HCT). Currently, the drug is in Phase I trial for the treatment of hematologic malignancies. 

Further product details are provided in the report……..

TCR Therapy: Therapeutic Assessment

This segment of the report provides insights about the different TCR Therapy drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in TCR Therapy

• There are approx. 50+ key companies which are developing the therapies for TCR Therapy. The companies which have their TCR Therapy drug candidates in the most advanced stage, i.e. Phase III include, Immunocore. 

Phases

DelveInsight’s report covers around 100+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of 
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

TCR Therapy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as 

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

TCR Therapy: Pipeline Development Activities 

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses TCR Therapy therapeutic drugs key players involved in developing key drugs. 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging TCR Therapy drugs.

TCR Therapy Report Insights

• TCR Therapy Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

TCR Therapy Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing TCR Therapy drugs?
• How many TCR Therapy drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of TCR Therapy?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the TCR Therapy therapeutics? 
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? 
• What are the clinical studies going on for TCR Therapy and their status?
• What are the key designations that have been granted to the emerging drugs?